CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
This trial will test the hypothesis that the administration of CF101, a novel
anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and
symptoms of the disease. CF101 effect will be in comparison to MTX in this study population.